secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARTIVION, INC. (AORT)
CIK:        0000784199
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0000784199-23-000084
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Artivion Q1 revenue $83.2M (+8% GAAP, +10% constant currency); raises FY guidance
--------------------------------------------------------------------------------

- Net loss ($13.5M) or ($0.33)/share; non-GAAP net income $769k ($0.02)/share.
- On-X revenue up 24% constant currency; aortic stent grafts up 8% constant currency.
- FY 2023 revenue guidance raised to $337-348M (prev. $331-343M); constant currency growth now 9-12%.
- Adjusted EBITDA guidance increased to >$52M (prev. >$50M); EBITDA growth >25% YoY expected.
- FDA issued Approvable Letter for PerClot PMA; $14.3M milestone payment expected after final approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/784199/000078419923000084/0000784199-23-000084-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/784199/000078419923000084/aort-20230504.htm
  HTML page:      https://secwatch.observer/filing/0000784199-23-000084

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer